Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 2/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | CCR3 | P51677 | 1/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.53 |
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.48 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1314774 | 0.87 | OPRL1 (0.63) | OPRL1POLBCYP3A4HSD17B10CCR3 | |
| SCHEMBL2695038 | 0.85 | OPRL1 (0.61) | OPRL1POLBCYP3A4HSD17B10CCR3 | |
| SCHEMBL27152373 | 0.85 | OPRL1 (0.61) | OPRL1POLBCYP3A4HSD17B10CCR3 | |
| SCHEMBL10447143 | 0.84 | SLC6A3 (0.53) | OPRL1SIGMAR1OPRM1 | |
| SCHEMBL7689578 | 0.83 | OPRL1 (0.63) | OPRL1POLBCYP3A4HSD17B10CCR3 | |
| SCHEMBL1366704 | 0.81 | OPRL1 (0.65) | OPRL1POLBCYP3A4HSD17B10CCR3 | |
| SCHEMBL7406058 | 0.81 | OPRL1 (0.65) | OPRL1POLBCYP3A4HSD17B10CCR3 | |
| SCHEMBL18826008 | 0.81 | KMT2A (0.62) | OPRL1POLBCYP3A4HSD17B10ALDH1A1 | |
| SCHEMBL3034128 | 0.81 | OPRL1 (0.59) | OPRL1POLBCYP3A4HSD17B10CCR3 | |
| SCHEMBL27840153 | 0.81 | OPRL1 (0.56) | OPRL1POLBCYP3A4HSD17B10CCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3371164-B1 | N-[2-(1-BENZYLPIPERIDIN-4-YL)ETHYL]-4-(PYRAZIN-2-YL)-PIPERAZINE-1-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS MUSCARINIC RECEPTOR 4 (M4) ANTAGONISTS FOR TREATING NEUROLOGICAL DISEASES | NEUROCRINE BIOSCIENCES INC (US) | 2022-03-16 | — | — | EP | disclosed |
| US-20210338653-A1 | N-[2-(1 -BENZYLPIPERIDIN-4-YL)ETHYL]-4-(PYRAZIN-2-YL)-PIPERAZINE-1 -CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS MUSCARINIC RECEPTOR 4 (M4) ANTAGONISTS FOR TREATING NEUROLOGICAL DISEASES | NEUROCRINE BIOSCIENCES, INC. | 2021-11-04 | — | — | US | disclosed |
| US-20210338653-A1 | N-[2-(1 -BENZYLPIPERIDIN-4-YL)ETHYL]-4-(PYRAZIN-2-YL)-PIPERAZINE-1 -CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS MUSCARINIC RECEPTOR 4 (M4) ANTAGONISTS FOR TREATING NEUROLOGICAL DISEASES | NEUROCRINE BIOSCIENCES, INC. | 2021-11-04 | — | — | US | disclosed |
| CN-108349936-B | Compounds as muscarinic receptor 4 antagonists | 纽罗克里生物科学有限公司 | 2021-10-01 | — | — | CN | disclosed |
| US-11033539-B2 | Compounds of formulas (VII), (VIII), (IX), (XI), (XII), (XIII), and (XIV) as muscarinic receptor 4(M4) antagonists for treating neurological diseases | NEUROCRINE BIOSCIENCES, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-11033539-B2 | Compounds of formulas (VII), (VIII), (IX), (XI), (XII), (XIII), and (XIV) as muscarinic receptor 4(M4) antagonists for treating neurological diseases | NEUROCRINE BIOSCIENCES, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-20180325887-A1 | N-[2-(1-BENZYLPIPERIDIN-4-YL)ETHYL]-4-(PYRAZIN-2-YL)-PIPERAZINE-1-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS MUSCARINIC RECEPTOR 4 (M4) ANTAGONISTS FOR TREATING NEUROLOGICAL DISEASES | NEUROCRINE BIOSCIENCES, INC. | 2018-11-15 | — | — | US | disclosed |
| EP-3371164-A1 | N-[2-(1 -BENZYLPIPERIDIN-4-YL)ETHYL]-4-(PYRAZIN-2-YL)-PIPERAZINE-1 -CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS MUSCARINIC RECEPTOR 4 (M4) ANTAGONISTS FOR TREATING NEUROLOGICAL DISEASES | NEUROCRINE BIOSCIENCES, INC. (US) | 2018-09-12 | — | — | EP | disclosed |
| WO-2017079641-A1 | N-[2-(1 -BENZYLPIPERIDIN-4-YL)ETHYL]-4-(PYRAZIN-2-YL)-PIPERAZINE-1 -CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS MUSCARINIC RECEPTOR 4 (M4) ANTAGONISTS FOR TREATING NEUROLOGICAL DISEASES | NEUROCRINE BIOSCIENCES, INC. (US) | 2017-05-11 | — | — | WO | disclosed |
| WO-2017079641-A1 | N-[2-(1 -BENZYLPIPERIDIN-4-YL)ETHYL]-4-(PYRAZIN-2-YL)-PIPERAZINE-1 -CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS MUSCARINIC RECEPTOR 4 (M4) ANTAGONISTS FOR TREATING NEUROLOGICAL DISEASES | NEUROCRINE BIOSCIENCES, INC. (US) | 2017-05-11 | — | — | WO | disclosed |
| EP-1874783-A1 | SUBSTITUTED OXA-DIAZA-SPIRO-[5.5]-UNDECANONE DERIVATIVES AND THEIR USE AS NEUROKININ ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-01-09 | — | — | EP | disclosed |
| EP-1846411-A2 | ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2007-10-24 | — | — | EP | disclosed |
| CN-1298705-C | Novel piperidine-4-sulfamide compound, its preparing method and medicinal composition containing them | ADIR (FR) | 2007-02-07 | — | — | CN | disclosed |
| WO-2006094934-A1 | SUBSTITUTED OXA-DIAZA-SPIRO-[5.5]-UNDECANONE DERIVATIVES AND THEIR USE AS NEUROKININ ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-09-14 | — | — | WO | disclosed |
| WO-2006081289-A2 | ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2006-08-03 | — | — | WO | disclosed |
| EP-1122254-B1 | 4-Sulfonamide piperidine derivatives, method for their preparation and phamaceutical compositions containing them | SERVIER LAB (FR) | 2005-04-27 | — | — | EP | disclosed |
| US-6323217-B2 | CARDIOVASCULAR DISORDERS | ADIR ET COMPAGNIE (FR) | 2001-11-27 | — | — | US | disclosed |
| US-20010034352-A1 | Piperidine-4 sulphonamide compounds | LES LABORATOIRES SERVIER (FR) | 2001-10-25 | — | — | US | disclosed |
| CN-1314345-A | Novel piperidine-4-sulfamide compound, its preparing method and medicinal composition containing them | ADIR (FR) | 2001-09-26 | — | — | CN | disclosed |
| EP-1122254-A2 | 4-Sulfonamide piperidine derivatives, method for their preparation and phamaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 2001-08-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010034352-A1 | Piperidine-4 sulphonamide compounds | KDR, GLS, FLT1 | OPRL1 1235/4885POLB 756/4885CYP3A4 204/4885 |
| US-11033539-B2 | Compounds of formulas (VII), (VIII), (IX), (XI), (XII), (XIII), and (XIV) as muscarinic receptor 4(M4) antagonists for treating neurological diseases | CHRM2, CHRM4, CHRM1 | OPRL1 402/4885POLB 2344/4885CYP3A4 358/4885 |
| US-20180325887-A1 | N-[2-(1-BENZYLPIPERIDIN-4-YL)ETHYL]-4-(PYRAZIN-2-YL)-PIPERAZINE-1-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS MUSCARINIC RECEPTOR 4 (M4) ANTAGONISTS FOR TREATING NEUROLOGICAL DISEASES | CHRM1, CHRM2, CHRM4 | OPRL1 169/4885POLB 3035/4885CYP3A4 1276/4885 |
| US-20210338653-A1 | N-[2-(1 -BENZYLPIPERIDIN-4-YL)ETHYL]-4-(PYRAZIN-2-YL)-PIPERAZINE-1 -CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS MUSCARINIC RECEPTOR 4 (M4) ANTAGONISTS FOR TREATING NEUROLOGICAL DISEASES | CHRM2, CHRM1, CHRM4 | OPRL1 176/4885POLB 2969/4885CYP3A4 1459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.